Articles On Cellmid (ASX:CDY)

Signing the agreement is in line with Cellmid’s strategic plan released in February 2019 targeting an Australian national retail partnership.

Brian McGee has been instrumental in securing new partnerships, including the recently announced deals with Beauty Collection, Macys.com, Rymax and Dermstore, which are expected to deliver material growth in the US business.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The company has also raised $1.5 million via a share placement to institutional and sophisticated investors.

On Stockhead today: gold is good, but which miners offer the best returns, how ASX pot stocks are maturing, Orthocell’s technology might have saved Superman and Clinuvel’s FDA approval caps off 4000% rise. But first:   The day ahead Today t...

The midkine and consumer health asset holder is aiming for operational profitability for its consumer business by 2020.

Europe Expansion: Cellmid has entered into a supply agreement for its évolis® Professional anti-aging hair care and hair loss products with leading European beauty retailer, Douglas GmbH. China Expansion: Cellmid has signed an exclusive dis...

These new channels and partners are expected to continue to drive consumer health revenue growth in Europe and China.

Cellmid (ASX: CDY) has launched into Europe after securing a distribution agreement with Douglas GmbH for its evolis professional anti-aging hair care and hair loss products, while at the same time collaring a distribution agreement in Chin...

New CEO Appointment - Bart Wuurman On the 1st June 2019, Bart Wuurman became the CEO of Lyramid, which holds Cellmid's Midkine portfolio. Mr. Wuuran's mandate is to accelerate partnering discussions and to explore opportunities to fully exp...

Accelerating consumer health revenue growth: Consumer health revenue growth of 30% in FY2019, up from 25% in FY2018. Improved operating results: Consumer health operating results improved with a 42% reduction in operating loss to $0.7 milli...

The company sells clinically proven hair loss products in Japan, the US, China, Australia, Europe and Asia.

The clinical development milestone adds value to a midkine patent portfolio open to partnering.

Cellmid Limited outlines key components for FY2020 growth strategy

Avangen is engaged in the development and sale of clinically validated anti-ageing products for skin, hair and body.

Of all the companies you would expect a tech investor and director to buy into, a healthy fast food chain is unlikely to be on your list. But WiseTech’s Michael Gregg has bought a 6.82 per cent stake in Oliver’s Real Foods (ASX: OLI). He pa...

Australia’s cannabis industry continues to edge forward under the watchful eye of regulators. For now, it’s the Office of Drug Control’s world — and domestic cannabis companies just live in it. Scroll down for more ASX cannabis news >&gt...

Advangen is the company’s wholly-owned subsidiary engaged in development and sale of first in class, best in class clinically validated anti-ageing products.

The global anti-counterfeit packaging market is experiencing a shift with the significant growth in demand due to the ever-expanding manufacturing activities across the world. Particularly, there is a strong growth in the demand from the fo...

Maria Halasz has recently lifted her total holding to almost 2.2 million shares through acquiring a further 12,000 shares.